344 results on '"D'Addio, Francesca"'
Search Results
102. Role of Podocyte B7-1 in Diabetic Nephropathy
- Author
-
Fiorina, Paolo, primary, Vergani, Andrea, additional, Bassi, Roberto, additional, Niewczas, Monika A., additional, Altintas, Mehmet M., additional, Pezzolesi, Marcus G., additional, D’Addio, Francesca, additional, Chin, Melissa, additional, Tezza, Sara, additional, Ben Nasr, Moufida, additional, Mattinzoli, Deborah, additional, Ikehata, Masami, additional, Corradi, Domenico, additional, Schumacher, Valerie, additional, Buvall, Lisa, additional, Yu, Chih-Chuan, additional, Chang, Jer-Ming, additional, La Rosa, Stefano, additional, Finzi, Giovanna, additional, Solini, Anna, additional, Vincenti, Flavio, additional, Rastaldi, Maria Pia, additional, Reiser, Jochen, additional, Krolewski, Andrzej S., additional, Mundel, Peter H., additional, and Sayegh, Mohamed H., additional
- Published
- 2014
- Full Text
- View/download PDF
103. Islet Transplantation Stabilizes Hemostatic Abnormalities and Cerebral Metabolism in Individuals With Type 1 Diabetes
- Author
-
D’Addio, Francesca, primary, Maffi, Paola, additional, Vezzulli, Paolo, additional, Vergani, Andrea, additional, Mello, Alessandra, additional, Bassi, Roberto, additional, Nano, Rita, additional, Falautano, Monica, additional, Coppi, Elisabetta, additional, Finzi, Giovanna, additional, D’Angelo, Armando, additional, Fermo, Isabella, additional, Pellegatta, Fabio, additional, La Rosa, Stefano, additional, Magnani, Giuseppe, additional, Piemonti, Lorenzo, additional, Falini, Andrea, additional, Folli, Franco, additional, Secchi, Antonio, additional, and Fiorina, Paolo, additional
- Published
- 2013
- Full Text
- View/download PDF
104. 5-methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients.
- Author
-
Cianciolo, Giuseppe, La Manna, Gaetano, Colì, Luigi, Donati, Gabriele, D’Addio, Francesca, Persici, Elisa, Comai, Giorgia, Wratten, Marylou, Dormi, Ada, Mantovani, Vilma, Grossi, Gabriele, Stefoni, Sergio, Colì, Luigi, and D'Addio, Francesca
- Abstract
Background: Hemodialysis (HD) patients have a greatly increased risk of cardiovascular morbidity and mortality. For this reason, attempts are often made to normalize hyperhomocysteinemia. This randomized prospective study sought to determine which risk factors are predictors of mortality and whether high doses of folates or 5-methyltetrahydrofolate (5-MTHF) could improve hyperhomocysteinemia and survival in HD patients.Methods: 341 patients were divided into two groups: group A was treated with 50 mg i.v. 5-MTHF, and group B was treated with 5 mg/day oral folic acid. Both groups received i.v. vitamin B(6) and B(12). By dividing patients into C-reactive protein (CRP) quartiles, group A had the highest survival for CRP <12 mg/l, whereas no survival difference was found for group B. CRP was the only predictive risk factor for death (RR 1.17, range 1.04-1.30, p = 0.02). Dialysis age, hyperhomocysteinemia, methylenetetrahydrofolate reductase polymorphism, albumin, lipoprotein (a) and folate did not influence mortality risk. Survival in group A was higher than that in group B, namely 36.2 +/- 20.9 vs. 26.1 +/- 22.2 months (p = 0.003).Results: Our results suggest that CRP, but not hyperhomocysteinemia, is the main risk factor for mortality in HD patients receiving vitamin supplements. Intravenous 5-MTHF seems to improve survival in HD patients independent from homocysteine lowering. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
105. CD160Ig Fusion Protein Targets a Novel Costimulatory Pathway and Prolongs Allograft Survival
- Author
-
D’Addio, Francesca, primary, Ueno, Takuya, additional, Clarkson, Michael, additional, Zhu, Baogong, additional, Vergani, Andrea, additional, Freeman, Gordon J., additional, Sayegh, Mohamed H., additional, Ansari, Mohammed Javeed I., additional, Fiorina, Paolo, additional, and Habicht, Antje, additional
- Published
- 2013
- Full Text
- View/download PDF
106. Long-Term Heart Transplant Survival by Targeting the Ionotropic Purinergic Receptor P2X7
- Author
-
Vergani, Andrea, primary, Tezza, Sara, additional, D’Addio, Francesca, additional, Fotino, Carmen, additional, Liu, Kaifeng, additional, Niewczas, Monika, additional, Bassi, Roberto, additional, Molano, R. Damaris, additional, Kleffel, Sonja, additional, Petrelli, Alessandra, additional, Soleti, Antonio, additional, Ammirati, Enrico, additional, Frigerio, Maria, additional, Visner, Gary, additional, Grassi, Fabio, additional, Ferrero, Maria E., additional, Corradi, Domenico, additional, Abdi, Reza, additional, Ricordi, Camillo, additional, Sayegh, Mohamed H., additional, Pileggi, Antonello, additional, and Fiorina, Paolo, additional
- Published
- 2013
- Full Text
- View/download PDF
107. Prolonged, Low-Dose Anti-Thymocyte Globulin, Combined with CTLA4-Ig, Promotes Engraftment in a Stringent Transplant Model
- Author
-
D’Addio, Francesca, primary, Boenisch, Olaf, additional, Magee, Ciara N., additional, Yeung, Melissa Y., additional, Yuan, Xueli, additional, Mfarrej, Bechara, additional, Vergani, Andrea, additional, Ansari, Mohammed Javeed, additional, Fiorina, Paolo, additional, and Najafian, Nader, additional
- Published
- 2013
- Full Text
- View/download PDF
108. The Link between the PDL1 Costimulatory Pathway and Th17 in Fetomaternal Tolerance
- Author
-
D’Addio, Francesca, primary, Riella, Leonardo V., additional, Mfarrej, Bechara G., additional, Chabtini, Lola, additional, Adams, La Tonya, additional, Yeung, Melissa, additional, Yagita, Hideo, additional, Azuma, Miyuki, additional, Sayegh, Mohamed H., additional, and Guleria, Indira, additional
- Published
- 2011
- Full Text
- View/download PDF
109. Kidney-Pancreas Transplantation Is Associated With Near-Normal Sexual Function in Uremic Type 1 Diabetic Patients
- Author
-
Salonia, Andrea, primary, D'Addio, Francesca, additional, Gremizzi, Chiara, additional, Briganti, Alberto, additional, Dehò, Federico, additional, Caldara, Rossana, additional, Orsenigo, Elena, additional, Staudacher, Carlo, additional, Socci, Carlo, additional, Rigatti, Patrizio, additional, Secchi, Antonio, additional, Montorsi, Francesco, additional, and Fiorina, Paolo, additional
- Published
- 2011
- Full Text
- View/download PDF
110. Targeting the CXCR4–CXCL12 Axis Mobilizes Autologous Hematopoietic Stem Cells and Prolongs Islet Allograft Survival via Programmed Death Ligand 1
- Author
-
Fiorina, Paolo, primary, Jurewicz, Mollie, additional, Vergani, Andrea, additional, Petrelli, Alessandra, additional, Carvello, Michele, additional, D’Addio, Francesca, additional, Godwin, Jonathan G., additional, Law, Kenneth, additional, Wu, Erxi, additional, Tian, Ze, additional, Thoma, Gebhard, additional, Kovarik, Jiri, additional, La Rosa, Stefano, additional, Capella, Carlo, additional, Rodig, Scott, additional, Zerwes, Hans-Guenter, additional, Sayegh, Mohamed H., additional, and Abdi, Reza, additional
- Published
- 2011
- Full Text
- View/download PDF
111. TIM-3: A Novel Regulatory Molecule of Alloimmune Activation
- Author
-
Boenisch, Olaf, primary, D’Addio, Francesca, additional, Watanabe, Toshihiko, additional, Elyaman, Wassim, additional, Magee, Ciara N., additional, Yeung, Melissa Y., additional, Padera, Robert F., additional, Rodig, Scott J., additional, Murayama, Takaya, additional, Tanaka, Katsunori, additional, Yuan, Xueli, additional, Ueno, Takuya, additional, Jurisch, Anke, additional, Mfarrej, Bechara, additional, Akiba, Hisaya, additional, Yagita, Hideo, additional, and Najafian, Nader, additional
- Published
- 2010
- Full Text
- View/download PDF
112. A Novel Clinically Relevant Approach to Tip the Balance Toward Regulation in Stringent Transplant Model
- Author
-
D'Addio, Francesca, primary, Yuan, Xueli, additional, Habicht, Antje, additional, Williams, John, additional, Ruzek, Melanie, additional, Iacomini, John, additional, Turka, Laurence A., additional, Sayegh, Mohamed H., additional, Najafian, Nader, additional, and Ansari, M. Javeed, additional
- Published
- 2010
- Full Text
- View/download PDF
113. Preclinical design of less immunogenic biologics: Tregitopes and Tolerance (144.28)
- Author
-
Buhlmann, Janet, primary, Najafian, Nader, additional, Hui, Daniel, additional, D'Addio, Francesca, additional, Mingozzi, Federico, additional, Moise, Lenny, additional, De Groot, Lesllie, additional, Keegan, Achsah, additional, Hui, Katherine, additional, Sayegh, Mohamed, additional, Scott, David, additional, and De Groot, Anne, additional
- Published
- 2010
- Full Text
- View/download PDF
114. Response to Comment on D'Addio et al. Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccines in a Cohort of Patients With Type 1 Diabetes. Diabetes 2022;71:1800–1806.
- Author
-
D'Addio, Francesca and Fiorina, Paolo
- Abstract
The authors respond to a comment on their a study on the safety and immunogenicity of the severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with type 1 diabetes. Topics discussed include the alteration in T-cell immune response in patients with type 1 diabetes following vaccination, and the exclusion of asymptomatic coronavirus disease 2019 in their study population.
- Published
- 2022
- Full Text
- View/download PDF
115. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy
- Author
-
Yuan, Xueli, primary, Paez-Cortez, Jesus, additional, Schmitt-Knosalla, Isabela, additional, D'Addio, Francesca, additional, Mfarrej, Bechara, additional, Donnarumma, Michela, additional, Habicht, Antje, additional, Clarkson, Michael R., additional, Iacomini, John, additional, Glimcher, Laurie H., additional, Sayegh, Mohamed H., additional, and Ansari, M. Javeed, additional
- Published
- 2008
- Full Text
- View/download PDF
116. Interleukin-10+ Regulatory B Cells Arise Within Antigen-Experienced CD40+ B Cells to Maintain Tolerance to Islet Autoantigens.
- Author
-
Kleffel, Sonja, Vergani, Andrea, Tezza, Sara, Ben Nasr, Moufida, Niewczas, Monika A., Wong, Susan, Bassi, Roberto, D'Addio, Francesca, Schatton, Tobias, Abdi, Reza, Atkinson, Mark, Sayegh, Mohamed H., Li Wen, Wasserfall, Clive H., O'Connor, Kevin C., and Fiorina, Paolo
- Subjects
B cells ,AUTOIMMUNE diseases ,LABORATORY mice ,OBESE-hyperglycemic syndrome ,T cells - Abstract
Impaired regulatory B cell (Breg) responses are associated with several autoimmune diseases in humans; however, the role of Bregs in type 1 diabetes (T1D) remains unclear. We hypothesized that naturally occurring, interleukin-10 (IL-10)-producing Bregs maintain tolerance to islet autoantigens, and that hyperglycemic nonobese diabetic (NOD) mice and T1D patients lack these potent negative regulators. IgV
H transcriptome analysis revealed that islet-infiltrating B cells in long-term normoglycemic (Lnglc) NOD, which are naturally protected from diabetes, are more antigen-experienced and possess more diverse B-cell receptor repertoires compared to those of hyperglycemic (Hglc) mice. Importantly, increased levels of Breg-promoting CD40+ B cells and IL-10-producing B cells were found within islets of Lnglc compared to Hglc NOD. Likewise, healthy individuals showed increased frequencies of both CD40+ and IL-10+ B cells compared to T1D patients. Rituximab-mediated B-cell depletion followed by adoptive transfer of B cells from Hglc mice induced hyperglycemia in Lnglc human CD20 transgenic NOD mouse models. Importantly, both murine and human IL-10+ B cells significantly abrogated T-cell-mediated responses to self- or islet-specific peptides ex vivo. Together, our data suggest that antigen-matured Bregs may maintain tolerance to islet autoantigens by selectively suppressing autoreactive T-cell responses, and that Hglc mice and individuals with T1D lack this population of Bregs. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
117. Harnessing the immunological properties of stem cells as a therapeutic option for diabetic nephropathy.
- Author
-
D'Addio, Francesca, Trevisani, Alessio, Ben Nasr, Moufida, Bassi, Roberto, El Essawy, Basset, Abdi, Reza, Secchi, Antonio, and Fiorina, Paolo
- Subjects
- *
STEM cell treatment , *IMMUNOLOGY , *DIABETIC nephropathies , *TYPE 1 diabetes , *TYPE 2 diabetes , *THERAPEUTICS - Abstract
Diabetic nephropathy is the leading and possibly the most devastating complication of diabetes, with a prevalence ranging from 25 to 40 % in diabetic individuals, and as such represents an important challenge for public health worldwide. As a major cause of end-stage renal disease, diabetic nephropathy also accounts for a large proportion of deaths in diabetic individuals. To date, therapeutic options for overt diabetic nephropathy include medical interventions to reduce blood glucose levels and to control blood pressure and proteinuria. Recent evidence suggests a strong role for inflammation in the development and progression of diabetic nephropathy. Various immune cells, cytokines and chemokines have been implicated in the onset of diabetic nephropathy, while immune-related transcription factors and adhesion molecules have been correlated with the establishment of a renal proinflammatory microenvironment. Both inflammation and immune activation may promote severe distress in the kidney, with subsequent increased local fibrosis, ultimately leading to the development of end-stage renal disease. Stem cells are undifferentiated cells capable of regenerating virtually any organ or tissue and bearing important immunoregulatory and anti-inflammatory properties. Due to the aforementioned considerations, significant interest has been ignited with regard to the use of stem cells as novel therapeutics for diabetic nephropathy. Here, we will be examining in detail how anti-inflammatory properties of different populations of stem cells may offer novel therapy for the treatment of diabetic nephropathy. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
118. Standard Heparin versus Low-Molecular-Weight Heparin
- Author
-
Stefoni, Sergio, primary, Cianciolo, Giuseppe, additional, Donati, Gabriele, additional, Colì, Luigi, additional, La Manna, Gaetano, additional, Raimondi, Concettina, additional, Dalmastri, Vittorio, additional, Orlandi, Valentina, additional, and D’Addio, Francesca, additional
- Published
- 2002
- Full Text
- View/download PDF
119. Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in New-Onset Type 1 Diabetes: A Multicenter Analysis.
- Author
-
D'Addio, Francesca, Valderrama Vasquez, Alessandro, Ben Nasr, Moufida, Franek, Edward, Dalong Zhu, Lirong Li, Guang Ning, Snarski, Emilian, and Fiorina, Paolo
- Subjects
- *
TYPE 1 diabetes , *AUTOIMMUNE diseases , *HEMATOPOIETIC stem cells , *IMMUNOTHERAPY , *CYCLOPHOSPHAMIDE - Abstract
Type 1 diabetes (T1D) is one of the major autoimmune diseases affecting children and young adults worldwide. To date, the different immunotherapies tested have achieved insulin independence in <5% of treated individuals. Recently, a novel hematopoietic stem cell (HSC)-based strategy has been tested in individuals with new-onset T1D. The aim of this study was to determine the effects of autologous nonmyeloablative HSC transplantation in 65 individuals with new-onset T1D who were enrolled in two Chinese centers and one Polish center, pooled, and followed up for 48 months. A total of 59% of individuals with T1D achieved insulin independence within the first 6 months after receiving conditioning immunosuppression therapy (with antithymocyte globulin and cyclophosphamide) and a single infusion of autologous HSCs, and 32% remained insulin independent at the last time point of their follow-up. All treated subjects showed a decrease in HbA1c levels and an increase in C-peptide levels compared with pretreat-ment. Despite a complete immune system recovery (i.e., leukocyte count) after treatment, 52% of treated individuals experienced adverse effects. Our study suggests the following: 1) that remission of T1D is possible by combining HSC transplantation and immunosuppression; 2) that autologous nonmyeloablative HSC transplantation represents an effective treatment for selected individuals with T1D; and 3) that safer HSC-based therapeutic options are required. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
120. Prolonged, Low-Dose Anti-Thymocyte Globulin, Combined with CTLA4-Ig, Promotes Engraftment in a Stringent Transplant Model.
- Author
-
D'Addio, Francesca, Boenisch, Olaf, Magee, Ciara N., Yeung, Melissa Y., Xueli Yuan, Mfarrej, Bechara, Vergani, Andrea, Ansari, Mohammed Javeed, Fiorina, Paolo, and Najafian, Nader
- Subjects
- *
NEPHROTOXICOLOGY , *CALCINEURIN , *IMMUNOSUPPRESSION , *TRANSPLANTATION of organs, tissues, etc. , *GLOBULINS , *T cells - Abstract
Background: Despite significant nephrotoxicity, calcineurin inhibitors (CNIs) remain the cornerstone of immunosuppression in solid organ transplantation. We, along with others, have reported tolerogenic properties of anti-thymocyte globulin (ATG, Thymoglobulin®), evinced by its ability both to spare Tregs from depletion in vivo and, when administered at low, non- depleting doses, to expand Tregs ex vivo. Clinical trials investigating B7/CD28 blockade (LEA29Y, Belatacept) in kidney transplant recipients have proven that the replacement of toxic CNI use is feasible in selected populations. Methods: Rabbit polyclonal anti-murine thymocyte globulin (mATG) was administered as induction and/or prolonged, low- dose therapy, in combination with CTLA4-Ig, in a stringent, fully MHC-mismatched murine skin transplant model to assess graft survival and mechanisms of action. Results: Prolonged, low-dose mATG, combined with CTLA4-Ig, effectively promotes engraftment in a stringent transplant model. Our data demonstrate that mATG achieves graft acceptance primarily by promoting Tregs, while CTLA4-Ig enhances mATG function by limiting activation of the effector T cell pool in the early stages of treatment, and by inhibiting production of anti-rabbit antibodies in the maintenance phase, thereby promoting regulation of alloreactivity. Conclusion: These data provide the rationale for development of novel, CNI-free clinical protocols in human transplant recipients. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
121. NUOVI ASPETTI IMMUNOLOGICI DEL TRAPIANTO DI RENE IN ETÀ PEDIATRICA.
- Author
-
D'Addio, Francesca, Vergani, Andrea, Di Fenza, Raffaele, Tezza, Sara, Bassi, Roberto, and Fiorina, Paolo
- Published
- 2012
122. The Link between the PDL1 Costimulatory Pathway and Th17 in Fetomaternal Tolerance.
- Author
-
D'Addio, Francesca, Riella, Leonardo V., Mfarrej, Bechara G., Chabtini, Lola, Adams, La Tonya, Yeung, Melissa, Yagita, Hideo, Azuma, Miyuki, Sayegh, Mohamed H., and Guleria, Indira
- Subjects
- *
VERTICAL transmission (Communicable diseases) , *T cells , *INTERLEUKINS , *APOPTOSIS , *TRANSGENIC mice - Abstract
Fetomaternal tolerance has been shown to depend both on regulatory T cells (Tregs) and negative signals from the PD1-PDL1 costimulatory pathway. More recently, IL-17-producing T cells (Th17) have been recognized as a barrier in inducing tolerance in transplantation. In this study, we investigate the mechanisms of PDL1-mediated regulation of fetomaternal tolerance using an alloantigen-specific CD4+ TCR transgenic mouse model system (ABM-tg mouse). PDL1 blockade led to an increase in embryo resorption and a reduction in litter size. This was associated with a decrease in Tregs, leading to a lower Treg/effector T cell ratio. Moreover, PDL1 blockade inhibited Ag-specific alloreactive T cell apoptosis and induced apoptosis of Tregs and a shift toward higher frequency of Th17 cells, breaking fetomaternal tolerance. These Th17 cells arose predominantly from CD4+Foxp3- cells, rather than from conversion of Tregs. Locally in the placenta, similar decrease in regulatory and apoptotic markers was observed by real-time PCR. Neutralization of IL-17 abrogated the anti-PDL1 effect on fetal survival rate and restored Treg numbers. Finally, the adoptive transfer of Tregs was also able to improve fetal survival in the setting of PDL1 blockade. This is to our knowledge the first report using an alloantigen-specific model that establishes a link between PDL1, Th17 cells, and fetomaternal tolerance. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
123. Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells.
- Author
-
Xueli Yuan, Ansari, M. Javeed, d'Addio, Francesca, Paez-Cortez, Jesus, Schmitt, Isabella, Donnarumma, Michela, Boenisch, Olaf, Xiaozhi Zhao, Popoola, Joyce, Clarkson, Michael R., Yagita, Hideo, Akiba, Hisaya, Freeman, Gordon J., lacomini, John, Turka, Laurence A., Glimcher, Laurie H., and Sayegh, Mohamed H.
- Subjects
CELL transplantation ,TRANSCRIPTION factors ,T cells ,LYMPHOCYTES ,HOMOGRAFTS - Abstract
The ability to induce durable transplantation tolerance predictably and consistently in the clinic is a highly desired but elusive goal. Progress is hampered by lack of appropriate experimental models in which to study resistance to transplantation tolerance: Here, we demonstrate that T helper 1-associated T box 21 transcription factor (Tbet) KO recipients exhibit allograft tolerance resistance specifically mediated by lL-17-producing CD8 T (T17) cells. Neutralization of IL-17 facilitates long-term cardiac allograft survival with combined T cell co-stimulation (CD28-CD80186 and CD154-CD4O) blockade in Tbet KO recipients. We have used this T17-biased Tbet KO model of allograft tolerance resistance to study the impact of targeting a T cell-co-stimulatory pathway, and demonstrate that targeting T cell Ig and mucin domain-1 (Tim-1) with anti-Tim-1 overcomes this resistance by specifically inhibiting the pathogenic IL-17-producing CD8 T17 cells. These data indicate that in the absence of Th1 immunity, CD8 T17 alloreactivity constitutes a barrier to transplantation tolerance. Targeting TIM-1 provides an approach to overcome resistance to tolerance in clinical transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
124. The IL-8-CXCR1/2 axis contributes to diabetic kidney disease.
- Author
-
Loretelli, Cristian, Rocchio, Francesca, D'Addio, Francesca, Ben Nasr, Moufida, Castillo-Leon, Eduardo, Dellepiane, Sergio, Vergani, Andrea, Abdelsalam, Ahmed, Assi, Emma, Maestroni, Anna, Usuelli, Vera, Bassi, Roberto, Pastore, Ida, Yang, Jun, El Essawy, Basset, Elased, Khalid M., Fadini, Gian Paolo, Ippolito, Elio, Seelam, Andy Joe, and Pezzolesi, Marcus
- Subjects
DIABETIC nephropathies ,TYPE 2 diabetes ,GLOMERULAR filtration rate ,DIABETES ,PEOPLE with diabetes ,DNA damage - Abstract
Inflammation has a major role in diabetic kidney disease. We thus investigated the role of the IL-8-CXCR1/2 axis in favoring kidney damage in diabetes. Urinary IL-8 levels were measured in 1247 patients of the Joslin Kidney Study in type 2 diabetes (T2D). The expression of IL-8 and of its membrane receptors CXCR1/CXCR2 was quantified in kidney tissues in patients with T2D and in controls. The effect of CXCR1/2 blockade on diabetic kidney disease was evaluated in db/db mice. IL-8 urinary levels were increased in patients with T2D and diabetic kidney disease, with the highest urinary IL-8 levels found in the patients with the largest decline in glomerular filtration rate, with an increased albumin/creatine ratio and the worst renal outcome. Moreover, glomerular IL-8 renal expression was increased in patients with T2D, as compared to controls. High glucose elicits abundant IL-8 secretion in cultured human immortalized podocytes in vitro. Finally, in diabetic db/db mice and in podocytes in vitro , CXCR1/2 blockade mitigated albuminuria, reduced mesangial expansion, decreased podocyte apoptosis and reduced DNA damage. The IL-8- CXCR1/2 axis may have a role in diabetic kidney disease by inducing podocyte damage. Indeed, targeting the IL-8-CXCR1/2 axis may reduce the burden of diabetic kidney disease. • The IL-8-CXCR1/2 axis is overactive in diabetic kidney disease • High glucose stimulates IL-8 secretion in podocytes in vitro • IL-8-CXCR1/2 axis blockade improves renal function in diabetic db/db mice • CXCR1/2 blockade in type 2 diabetes patients may reduce the burden of diabetic kidney disease [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
125. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy
- Author
-
Paez-Cortez, Jesus, Schmitt-Knosalla, Isabela, Mfarrej, Bechara, Donnarumma, Michela, Habicht, Antje, Clarkson, Michael R., Ansari, M. Javeed, Yuan, Xueli, D'Addio, Francesca, Iacomini, John J., Glimcher, Laurie Hollis, and Sayegh, Mohamed Hassan
- Abstract
T-bet plays a crucial role in Th1 development. We investigated the role of T-bet in the development of allograft rejection in an established MHC class II–mismatched (bm12 into B6) model of chronic allograft vasculopathy (CAV). Intriguingly, and in contrast to IFN-γ−/− mice that are protected from CAV, T-bet−/− recipients develop markedly accelerated allograft rejection accompanied by early severe vascular inflammation and vasculopathy, and infiltration by predominantly IL-17–producing CD4 T cells. Concurrently, T-bet−/− mice exhibit a T helper type 1 (Th1)–deficient environment characterized by profound IFN-γ deficiency, a Th2 switch characterized by increased production of interleukin (IL) 4, IL-5, IL-10, and IL-13 cytokines, as well as increased production of the proinflammatory cytokines IL-6, IL-12p40, and IL-17. Neutralization of IL-17 inhibits accelerated allograft rejection and vasculopathy in T-bet−/− mice. Interestingly, CD4 but not CD8 T cell deficiency in T-bet−/− mice affords dramatic protection from vasculopathy and facilitates long-term graft acceptance. This is the first study establishing that in the absence of Th1-mediated alloimmune responses, CD4 Th17 cells mediate an aggressive proinflammatory response culminating in severe accelerated allograft rejection and vasculopathy. These results have important implications for the development of novel therapies to target this intractable problem in clinical solid organ transplantation.
- Published
- 2008
- Full Text
- View/download PDF
126. Combined kidney liver transplantation: A single center experience
- Author
-
Mosconi, Giovanni, Scolari, Maria P., Feliciangeli, Giorgio, D Arcangelo, Giovanni Liviano, Andrea Buscaroli, D Addio, Francesca, Falaschini, Alessandra, Cappuccilli, Maria L., Faenza, Alessandro, Pinna, Antonio Davide, Stefoni, Sergio, Mosconi G, Scolari MP, Feliciangeli G, Liviano D’Arcangelo G, Buscaroli A, D’Addio F, Falaschini A, Cappuccilli ML, Faenza A, Pinna AD, and Stefoni S
127. Next-gen therapeutics to spare and expand beta-cell mass.
- Author
-
Bolla, Andrea Mario, Usuelli, Vera, Ben Nasr, Moufida, Frigerio, Sofia, Loretelli, Cristian, D'Addio, Francesca, and Fiorina, Paolo
- Subjects
- *
PANCREATIC beta cells , *TYPE 1 diabetes , *TYPE 2 diabetes - Abstract
The most effective and physiological way to treat hyperglycemia is to restore beta-cell function and to rescue production of endogenous insulin. Increasing evidence suggests that both type 1 and type 2 diabetes are characterized by a significant defect in beta-cell mass, leading to the manifestation of the disease. Novel alternative approaches are needed to spare and expand beta-cell mass in patients with diabetes. This review sets out to describe the latest findings on how to restore the beta-cell mass and function in both forms of diabetes to modulate their progression. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
128. Continuous glucose monitoring in patients with type 2 diabetes on hemodialysis.
- Author
-
Gallieni, Maurizio, De Salvo, Cristina, Lunati, Maria Elena, Rossi, Antonio, D'Addio, Francesca, Pastore, Ida, Sabiu, Gianmarco, Miglio, Roberta, Zuccotti, Gian Vincenzo, and Fiorina, Paolo
- Subjects
- *
TYPE 2 diabetes , *INSULIN , *BLOOD sugar , *PATIENT monitoring , *BLOOD sugar monitoring , *DIABETIC nephropathies , *GLYCOSYLATED hemoglobin , *GLUCOSE - Abstract
Diabetic kidney disease is the leading cause of end-stage kidney disease in high-income countries. The strict control of glycemic oscillations is the principal therapeutic target, but this could be hard to achieve in uremic patients due to their unpredictable insulin sensitivity. Currently, the evaluation of the glycemic profile relies on serum markers (glycated hemoglobin HbA1c, glycated albumin, and fructosamine), capillary glucose blood control (self-monitoring of blood glucose), and interstitial glucose control (continue glucose monitoring). We conducted a systematic review of published articles on continue glucose monitoring in hemodialysis patients with type 2 diabetes, which included 12 major articles. Four studies found significant fluctuations in glucose levels during hemodialysis sessions. All studies reported a higher mean amplitude of glucose variations on the hemodialysis day. Three studies agreed that continue glucose monitoring is better than glycated hemoglobin in detecting these abnormalities. Moreover, continue glucose monitoring was more accurate and perceived as easier to use by patients and their caregivers. In patients with type 2 diabetes on hemodialysis, glucose levels show different variation patterns than the patients on hemodialysis without diabetes. Considering manageability, accuracy, and cost-effectiveness, continue glucose monitoring could be the ideal diagnostic tool for the patient with diabetes on hemodialysis. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
129. Regulatory B Cells in Autoimmune Diabetes.
- Author
-
Nasr, Moufida Ben, Usuelli, Vera, Seelam, Andy Joe, D'Addio, Francesca, Abdi, Reza, Markmann, James F., and Fiorina, Paolo
- Subjects
- *
REGULATORY B cells , *DIABETES , *PHENOTYPES - Abstract
Since they were discovered almost three decades ago, a subset of B cells denoted as regulatory B cells (Bregs) have elicited interest throughout the immunology community. Many investigators have sought to characterize their phenotype and to understand their function and immunosuppressive mechanisms. Indeed, studies in murine models have demonstrated that Bregs possess varied phenotypic markers and could be classified into different subsets whose action and pivotal role depend on the pathological condition or stimuli. Similar conclusions were drawn in clinical settings delineating an analogous Breg population phenotypically resembling the murine Bregs that ultimately may be associated with a state of tolerance. Recent studies suggested that Bregs may play a role in the onset of autoimmune diabetes. This review will focus on deciphering the different subclasses of Bregs, their emerging role in autoimmune diabetes, and their potential use as a cell-based therapeutic. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
130. Embryonic stem cell extracts improve wound healing in diabetic mice.
- Author
-
Loretelli, Cristian, Ben Nasr, Moufida, Giatsidis, Giorgio, Bassi, Roberto, Lancerotto, Luca, D'Addio, Francesca, Valderrama-Vasquez, Alessandro, Scherer, Saja Sandra, Salvatore, Luca, Madaghiele, Marta, Abdelsalam, Ahmed, Ippolito, Elio, Assi, Emma, Usuelli, Vera, El Essawy, Basset, Sannino, Alessandro, Pietramaggiori, Giorgio, Zuccotti, Gian Vincenzo, Orgill, Dennis Paul, and Fiorina, Paolo
- Subjects
- *
EMBRYONIC stem cells , *WOUND healing , *SUPPRESSOR cells , *PEOPLE with diabetes , *ANIMAL models in research , *EXTRACTS - Abstract
Aims/hypothesis: Impaired wound healing significantly impacts morbidity and mortality in diabetic patients, necessitating the development of novel treatments to improve the wound healing process. We here investigated the topical use of acellular embryonic stem cell extracts (EXTs) in wound healing in diabetic db/db mice. Methods: Wounds were induced in diabetic db/db mice, which were subsequently treated with EXTs, with 3T3 fibroblast cell line protein extracts (3T3XTs) or with saline as a control. Pathology and mechanistic assays were then performed. Results: The in vivo topical administration of EXTs facilitates wound closure, contraction and re-epithelialization. Moreover, EXTs reduced the number of wound-infiltrating CD45+ inflammatory cells and increased the rate of repair and of angiogenesis as compared to controls. Interestingly, the EXT effect was partly enhanced by the use of a collagen-based biocompatible scaffold. In vivo, topical administration of EXTs increased the percentage of regulatory T cells in the wounded tissue, while in vitro EXT treatment reduced T cell-mediated IFN-γ production. Proteomic screening revealed 82 proteins differentially segregating in EXTs as compared to 3T3 extracts, with APEX1 identified as a key player for the observed immunomodulatory effect of EXTs. Conclusions: EXTs are endowed with immunoregulatory and anti-inflammatory properties; their use improves wound healing in diabetic preclinical models. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
131. The β-cell effect of verapamil-based treatment in patients with type 2 diabetes: a systematic review.
- Author
-
Carnovale, Carla, Dassano, Alice, Mosini, Giulia, Mazhar, Faizan, D'Addio, Francesca, Pozzi, Marco, Radice, Sonia, Fiorina, Paolo, and Clementi, Emilio
- Subjects
- *
TYPE 2 diabetes , *TREATMENT effectiveness , *META-analysis , *METABOLIC regulation - Abstract
Aims: The possibility that verapamil has new beneficial effects in diabetic patients in terms of an improvement in glycometabolic control has been put forward recently in several studies. However, to date the issue is still under debate. We conducted the first systematic review examining the impact of verapamil-based treatment on glycometabolic outcomes, in type 2 diabetes (T2D) patients. Methods: We searched the PubMed, MEDLINE, Embase, Cochrane and ClinicalTrials.gov up to 9 October 2018, for all studies evaluating whether verapamil-based treatment is associated with changes in glycated haemoglobin (HbA1c), fasting plasma glucose levels, glucose and C-peptide areas from baseline in humans, without restrictions for study type. Results: Plasma glucose levels were lowered significantly by verapamil-based treatment in patients with T2D (mean change − 13 ± 5.29; P = 0.049); HbA1c values were instead not affected by the drug (mean change − 0.10 ± 0.12; P = 0.453). In five studies, groups exposed to verapamil achieved lower value of glycometabolic outcomes: comparison with values recorded in control groups showed a significant difference, in terms of both HbA1c and plasma glucose levels. Conclusions: Despite the fact that plasma glucose levels were lowered significantly by verapamil-based treatment in patients with T2D (the HbA1c values were not affected by the drug), the clinical significance of the glycometabolic response induced by verapamil-based treatment remains unclear due to the high variety of sample size and type of studies presently available. Further experimental and clinical trials are needed to clarify unambiguously the role of verapamil in metabolic control. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
132. Daytime hypoglycemic episodes during the use of an advanced hybrid closed loop system.
- Author
-
Rossi, Antonio, Montefusco, Laura, Reseghetti, Elia, Pastore, Ida Fabrizia, Rossi, Giada, Usuelli, Vera, Loretelli, Cristian, Boci, Denisa, Ben Nasr, Moufida, D'Addio, Francesca, Bucciarelli, Loredana, Argenti, Sabrina, Morpurgo, Paola, Lunati, Maria Elena, and Fiorina, Paolo
- Subjects
- *
CLOSED loop systems , *TYPE 1 diabetes , *HYPOGLYCEMIA - Abstract
• Hybrid Closed Loop superiority in lowering the risk of hypoglycemia as compared to Low Glucose Suspend systems is supposed. • In this observational study we found more daytime hypoglycemic events with an Advanced Hybrid Closed Loop system. • Nighttime hypoglycemic events were similar. • Closed loop algorithm intervention was not related to hypoglycemia occurrence. • Time Below Range did not reflect the global hypoglycemia burden. The use of advanced hybrid closed loop systems is spreading due to the beneficial effects on glycometabolic control obtained in patients with type 1 diabetes. However, hypoglycemic episodes can be sometimes a matter of concern. We aim to compare the hypoglycemic risk of an advanced hybrid closed loop system and a predictive low glucose suspend sensor augmented pump. In this retrospective three months observational study, we included 30 patients using Medtronic Minimed™ 780G advanced hybrid closed loop system and 30 patients using a Medtronic Minimed™ predictive low glucose suspend sensor augmented pump. The advanced hybrid closed loop system reduced the time spent above 180 mg/dL threshold and increased the time in range as compared to the predictive low glucose suspend. No severe hypoglycemia occurred in both groups and no differences were observed in the percentage of time spent below 70 mg/dl and 54 mg/dl glucose threshold. Nevertheless, more hypoglycemic episodes were recorded during daytime, but not in nighttime, with the use of the advanced hybrid closed loop system. Our results confirmed the general improvement of glycemic outcomes obtained with the advanced hybrid closed loop system; however more hypoglycemic episodes during daytime were evident. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
133. Broadening horizons in mechanisms, management, and treatment of diabetic kidney disease.
- Author
-
Petrazzuolo, Adriana, Sabiu, Gianmarco, Assi, Emma, Maestroni, Anna, Pastore, Ida, Lunati, Maria Elena, Montefusco, Laura, Loretelli, Cristian, Rossi, Giada, Ben Nasr, Moufida, Usuelli, Vera, Xie, Yanan, Balasubramanian, Hari Baskar, Zocchi, Monica, El Essawy, Basset, Yang, Jun, D'Addio, Francesca, and Fiorina, Paolo
- Subjects
- *
DIABETIC nephropathies , *CHRONIC kidney failure , *GLOMERULAR filtration rate , *BASAL lamina , *PEOPLE with diabetes , *CELL death - Abstract
Diabetic kidney disease (DKD) is the first cause of end-stage kidney disease in patients with diabetes and its prevalence is increasing worldwide. It encompasses histological alterations that mainly affect the glomerular filtration unit, which include thickening of the basement membrane, mesangial cell proliferation, endothelial alteration, and podocyte injury. These morphological abnormalities further result in a persistent increase of urinary albumin-to-creatinine ratio and in a reduction of the estimated glomerular filtration rate. Several molecular and cellular mechanisms have been recognized, up to date, as major players in mediating such clinical and histological features and many more are being under investigation. This review summarizes the most recent advances in understanding cell death mechanisms, intracellular signaling pathways and molecular effectors that play a role in the onset and progression of diabetic kidney damage. Some of those molecular and cellular mechanisms have been already successfully targeted in preclinical models of DKD and, in some cases, strategies have been tested in clinical trials. Finally, this report sheds light on the relevance of novel pathways that may become therapeutic targets for future applications in DKD. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
134. eATP and autoimmune diabetes.
- Author
-
Loretelli, Cristian, Pastore, Ida, Lunati, Maria Elena, Abdelsalam, Ahmed, Usuelli, Vera, Assi, Emma, Fiorina, Emma, Loreggian, Lara, Balasubramanian, Hari Baskar, Xie, Yanan, Yang, Jun, El Essawy, Basset, Montefusco, Laura, D'Addio, Francesca, Ben Nasr, Moufida, and Fiorina, Paolo
- Subjects
- *
PURINERGIC receptors , *TYPE 1 diabetes , *PANCREAS transplantation , *IMMUNOLOGICAL tolerance , *T cells , *EXTRACELLULAR space - Abstract
The purine nucleotide adenosine triphosphate (ATP) is released into extracellular spaces as extracellular ATP (eATP) as a consequence of cell injury or death and activates the purinergic receptors. Once released, eATP may facilitate T-lymphocyte activation and differentiation. The purpose of this review is to elucidate the role of ATP-mediated signaling in the immunological events related to type 1 diabetes (T1D). T lymphocytes mediate immune response during the onset of T1D and promote pancreatic islet or whole pancreas rejection in transplantation. Recent data suggest a potential role for eATP in early steps of T1D onset and of allograft rejection. In different preclinical experimental models and clinical trials, several drugs targeting purinergic signaling have been employed to abrogate lymphocyte activation and differentiation, thus representing an achievable treatment to prevent/revert T1D or to induce long-term islet allograft function. In preclinical and clinical settings, eATP-signaling inhibition induces immune tolerance in autoimmune disease and in allotransplantation. In this view, the purinergic system may represent a novel therapeutic target for auto- and allo-immunity. [Display omitted] • Extracellular ATP plays a critical role in the auto- and allo-immune response. • Extracellular ATP is involved in the early stage of T1D. • Two P2X7 receptor loss of function mutations are protective against T1D. • P2X7 receptor is expressed in lymphocytes infiltrating islet allograft. • P2X7 receptor blockade reduces autoimmune response mediated by T cells. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
135. Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study.
- Author
-
Lazzaroni, Elisa, Lunati, Maria Elena, Montefusco, Laura, Pastore, Ida, Chebat, Enrica, Cimino, Vincenzo, Morpurgo, Paola Silvia, Muratori, Milena, Plebani, Laura, Bolla, Andrea, Rossi, Antonio, Vallone, Luciana, Gandolfi, Alessandra, Tinari, Camilla, D'Addio, Francesca, Nasr, Moufida Ben, Loretelli, Cristian, Scaranna, Cristiana, Bellante, Rosalia, and Manfrini, Roberto
- Subjects
- *
TYPE 2 diabetes , *KIDNEY physiology , *DIASTOLIC blood pressure , *INSULIN , *DAPAGLIFLOZIN , *SYSTOLIC blood pressure - Abstract
Dapagliflozin has been demonstrated to improve glycemic control, blood pressure, and body weight in type 2 diabetes mellitus (T2D); indeed, it can also reduce the risk of progression to renal failure, of hospitalization for heart failure and of cardiovascular death. We aim to investigate the acute effect of Dapagliflozin on kidney function in the common clinical practice in T2D. This is a study including 1402 patients with T2D recruited from 11 centers in Lombardia, Italy, who were evaluated at baseline and after 6 months of treatment with Dapagliflozin 10 mg per day. The primary outcome of the study was the change in HbA1c, while the secondary outcomes were modification of weight, BMI, systolic and diastolic pressure, creatinine, eGFR and albuminuria status. After 24 weeks of treatment with Dapagliflozin, a reduction in Hb1Ac was observed (−0.6 ± 1.8%) as well as in BMI (−1.5 ± 5.2 kg/m2). Statistically significant changes were also found for systolic and diastolic blood pressure, cholesterol and triglycerides. Interestingly, a statistically significant acute improvement of kidney function was evident. Our analyses confirm the beneficial effects of dapagliflozin after 6 months of therapy, with improvements of glycemic and lipid profiles, blood pressure, BMI. Finally, an acute positive effect on albuminuria and KIDGO classes was observed during a 6 months treatment with dapagliflozin in patients with T2D. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
136. Metabolomic Profiling in Individuals with a Failing Kidney Allograft
- Author
-
Alexander P. Lin, Valentina De Zan, Francesco De Cobelli, Sara Tezza, Massimo Venturini, Roberto Bassi, Anil Chandraker, Monika A. Niewczas, Moufida Ben Nasr, Antonio Secchi, Paolo Fiorina, Vera Usuelli, Luigi Biancone, Francesca D'Addio, Alessandro Valderrama-Vasquez, Basset El Essawy, Sai Merugumala, Stefania Bussolino, Bassi, Roberto, Niewczas, Monika A., Biancone, Luigi, Bussolino, Stefania, Merugumala, Sai, Tezza, Sara, D'Addio, Francesca, Nasr, Moufida Ben, Valderrama-vasquez, Alessandro, Usuelli, Vera, De Zan, Valentina, El Essawy, Basset, Venturini, Massimo, Secchi, Antonio, DE COBELLI, Francesco, Lin, Alexander, Chandraker, Anil, and Fiorina, Paolo
- Subjects
Genetics and Molecular Biology (all) ,Male ,0301 basic medicine ,Physiology ,030232 urology & nephrology ,lcsh:Medicine ,Urine ,Spectrum analysis techniques ,Biochemistry ,Medicine (all) ,Biochemistry, Genetics and Molecular Biology (all) ,chemistry.chemical_compound ,0302 clinical medicine ,Tandem Mass Spectrometry ,Medicine and Health Sciences ,Renal Transplantation ,Metabolites ,Two-dimensional NMR spectroscopy ,Choline ,lcsh:Science ,Kidney transplantation ,Kidney ,Multidisciplinary ,Middle Aged ,Body Fluids ,medicine.anatomical_structure ,Creatinine ,Female ,Two-Dimensional Correlation Spectroscopy ,Anatomy ,Glomerular Filtration Rate ,Research Article ,Adult ,medicine.medical_specialty ,Renal function ,Surgical and Invasive Medical Procedures ,Biology ,Creatine ,Urinary System Procedures ,03 medical and health sciences ,NMR spectroscopy ,Internal medicine ,medicine ,Humans ,Metabolomics ,Transplantation ,Renal Physiology ,lcsh:R ,Biology and Life Sciences ,Kidneys ,Renal System ,Organ Transplantation ,medicine.disease ,Kidney Transplantation ,Research and analysis methods ,Metabolism ,030104 developmental biology ,Endocrinology ,Agricultural and Biological Sciences (all) ,Correlation Spectroscopy ,chemistry ,Renal physiology ,Multivariate Analysis ,lcsh:Q ,Chromatography, Liquid - Abstract
Background Alteration of certain metabolites may play a role in the pathophysiology of renal allograft disease. Methods To explore metabolomic abnormalities in individuals with a failing kidney allograft, we analyzed by liquid chromatography-mass spectrometry (LC-MS/MS; for ex vivo profiling of serum and urine) and two dimensional correlated spectroscopy (2D COSY; for in vivo study of the kidney graft) 40 subjects with varying degrees of chronic allograft dysfunction stratified by tertiles of glomerular filtration rate (GFR; T1, T2, T3). Ten healthy non-allograft individuals were chosen as controls. Results LC-MS/MS analysis revealed a dose-response association between GFR and serum concentration of tryptophan, glutamine, dimethylarginine isomers (asymmetric [A]DMA and symmetric [S]DMA) and short-chain acylcarnitines (C4 and C12), (test for trend: T1-T3 = p
- Published
- 2017
137. TIM4 regulates the anti-islet Th2 alloimmune response
- Author
-
Laurence A. Turka, Erxi Wu, Ze Tian, Sara Tezza, James F. Markmann, David M. Rothstein, Melissa Chin, Kang M. Lee, Paolo Fiorina, Paola Maffi, Moufida Ben Nasr, Roberto Bassi, Francesca D'Addio, Mohamed H. Sayegh, Andrea Vergani, James I. Kim, Francesca Gatti, Antonio Secchi, Vergani, Andrea, Gatti, Francesca, Lee, Kang Mi, D’Addio, Francesca, Sara, Tezza, Chin, Melissa, Bassi, Roberto, Tian, Ze, Wu, Ex, Maffi, Paola, Ben, Nasr, Kim, Ji, Secchi, A, Markmann, James F, Turka, Laurance, Rothstein, David M, Sayegh, Mohamed H, and Paolo, Fiorina
- Subjects
Male ,Cellular differentiation ,Islets of Langerhans Transplantation ,lcsh:Medicine ,Autoimmune diabete ,Autoimmunity ,medicine.disease_cause ,Mice ,Mice, Inbred NOD ,Islet transplantation ,Membrane Protein ,Transplantation, Homologou ,NOD mice ,B-Lymphocytes ,Mice, Inbred BALB C ,geography.geographical_feature_category ,Regulatory cell ,Graft Survival ,B-Lymphocyte ,Cell Differentiation ,Middle Aged ,Islet ,Survival Rate ,Th1 Cell ,Cytokines ,Female ,Human ,Adult ,endocrine system ,medicine.drug_class ,Biomedical Engineering ,Biology ,Monoclonal antibody ,Article ,Diabetes Mellitus, Experimental ,Islets of Langerhans ,Immune system ,Th2 Cells ,Downregulation and upregulation ,medicine ,Animals ,Humans ,Transplantation, Homologous ,Th2 Cell ,Cytokine ,Transplantation ,geography ,Animal ,lcsh:R ,Costimulatory molecule ,Membrane Proteins ,Islets of Langerhan ,Cell Biology ,Th1 Cells ,Mice, Inbred C57BL ,Diabetes Mellitus, Type 1 ,Immunology ,Transcriptome - Abstract
The role of the novel costimulatory molecule TIM4 in anti-islet response is unknown. We explored TIM4 expression and targeting in Th1 (BALB/c islets into C57BL/6 mice) and Th2 (BALB/c islets into Tbet-/- C57BL/6 mice) models of anti-islet alloimmune response and in a model of anti-islet autoimmune response (diabetes onset in NOD mice). The targeting of TIM4, using the monoclonal antibody RMT4-53, promotes islet graft survival in a Th1 model, with 30% of the graft surviving in the long term; islet graft protection appears to be mediated by a Th1 to Th2 skewing of the immune response. Differently, in the Th2 model, TIM4 targeting precipitates graft rejection by further enhancing the Th2 response. The effect of anti-TIM4 treatment in preventing autoimmune diabetes was marginal with only minor Th1 to Th2 skewing. B-Cell depletion abolished the effect of TIM4 targeting. TIM4 is expressed on human B-cells and is upregulated in diabetic and islet-transplanted patients. Our data suggest a model in which TIM4 targeting promotes Th2 response over Th1 via B-cells. The targeting of TIM4 could become a component of an immunoregulatory protocol in clinical islet transplantation, aiming at redirecting the immune system toward a Th2 response.
- Published
- 2014
138. Vaccinome landscape in nearly 620,000 patients with diabetes.
- Author
-
D'Addio F, Lazzaroni E, Lunati ME, Preziosi G, Ercolanoni M, Turola G, Marrocu C, Cicconi G, Sharma S, Scarioni S, Montefusco L, Pastore I, Morpurgo PS, Rossi A, Gandolfi A, Tinari C, Rossi G, Ben Nasr M, Loretelli C, Fiorina RM, Grassa B, Terranova R, Bucciarelli L, Berra C, Cereda D, Zuccotti G, Borriello CR, and Fiorina P
- Abstract
Introduction: Type 1 (T1D) and type 2 diabetes (T2D) are associated with an elevated incidence of infectious diseases and a higher risk of infections-related hospitalization and death. In this study, we delineated the "vaccinome" landscape obtained with a large immunization schedule offered by the Regional Government of Lombardy in a cohort of 618,396 patients with diabetes (T1D and T2D)., Methods: Between September 2021 and September 2022, immunization coverage for influenza, meningococcus, pneumococcus, and herpes zoster was obtained from the public computerized registry of the healthcare system of Lombardy Region (Italy) in 618,396 patients with diabetes and in 9,534,087 subjects without diabetes. Type of diabetes, age, mortality, and hospitalizations were retrospectively analyzed in vaccinated and unvaccinated patients., Results: Among patients with diabetes (T1D and T2D), 44.6% received the influenza vaccine, 10.9% the pneumococcal vaccine, 2.5% the anti-meningococcus vaccine and 0.7% the anti-zoster vaccine. Patients with diabetes immunized for influenza, zoster and meningococcus showed a 2-fold overall reduction in mortality risk and a decrease in hospitalizations. A 3-fold lower risk of mortality and a decrease in hospitalizations for both cardiac and pulmonary causes were also observed after influenza, zoster, and meningococcus immunization in older patients with diabetes., Conclusions: Immunization coverage is still far from the recommended targets in patients with diabetes. Despite this, influenza vaccination protected nearly 3,800 per 100,000 patients with diabetes from risk of death. The overall impressive decrease in mortality and hospitalizations observed in vaccinated patients strengthens the need for scaling up the "vaccinome" landscape in patients with diabetes., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. See the journal About page for additional terms.)
- Published
- 2024
- Full Text
- View/download PDF
139. Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule.
- Author
-
Ben Nasr M, Usuelli V, Dellepiane S, Seelam AJ, Fiorentino TV, D'Addio F, Fiorina E, Xu C, Xie Y, Balasubramanian HB, Castillo-Leon E, Loreggian L, Maestroni A, Assi E, Loretelli C, Abdelsalam A, El Essawy B, Uccella S, Pastore I, Lunati ME, Sabiu G, Petrazzuolo A, Ducci G, Sacco E, Centofanti L, Venturini M, Mazzucchelli S, Mattinzoli D, Ikehata M, Castellano G, Visner G, Kaifeng L, Lee KM, Wang Z, Corradi D, La Rosa S, Danese S, Yang J, Markmann JF, Zuccotti GV, Abdi R, Folli F, and Fiorina P
- Subjects
- Animals, Mice, T-Lymphocytes immunology, T-Lymphocytes metabolism, Male, Heart Transplantation, Mice, Inbred BALB C, CD8-Positive T-Lymphocytes metabolism, CD8-Positive T-Lymphocytes immunology, Graft Survival immunology, Glucagon-Like Peptide-1 Receptor metabolism, Mice, Inbred C57BL, Islets of Langerhans Transplantation
- Abstract
Glucagon-like peptide-1 receptor (GLP-1R) is a key regulator of glucose metabolism known to be expressed by pancreatic β cells. We herein investigated the role of GLP-1R on T lymphocytes during immune response. Our data showed that a subset of T lymphocytes expresses GLP-1R, which is upregulated during alloimmune response, similarly to PD-1. When mice received islet or cardiac allotransplantation, an expansion of GLP-1R
pos T cells occurred in the spleen and was found to infiltrate the graft. Additional single-cell RNA sequencing (scRNA-seq) analysis conducted on GLP-1Rpos and GLP-1Rneg CD3+ T cells unveiled the existence of molecular and functional dissimilarities between both subpopulations, as the GLP-1Rpos are mainly composed of exhausted CD8 T cells. GLP-1R acts as a T cell-negative costimulatory molecule, and GLP-1R signaling prolongs allograft survival, mitigates alloimmune response, and reduces T lymphocyte graft infiltration. Notably, GLP-1R antagonism triggered anti-tumor immunity when tested in a preclinical mouse model of colorectal cancer., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2024 Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
140. TMEM219 regulates the transcription factor expression and proliferation of beta cells.
- Author
-
D'Addio F, Assi E, Maestroni A, Rossi G, Usuelli V, Petrazzuolo A, Nardini M, Loretelli C, Ben Nasr M, and Fiorina P
- Subjects
- Humans, Cell Proliferation, Transcription Factors metabolism, Diabetes Mellitus, Type 1 metabolism, Insulin-Secreting Cells metabolism, Insulinoma metabolism, MicroRNAs genetics, MicroRNAs metabolism, Pancreatic Neoplasms metabolism
- Abstract
Pancreatic beta cells replenishment is considered the next therapeutic option for type 1 diabetes; while stimulating endogenous beta cells proliferation is the "holy grail" for those patients with exhausted beta cell mass. Here we are demonstrating that the pro-apoptotic receptor TMEM219 is expressed in fetal pancreas, in beta cell precursors and in in vitro embryonic-derived endocrine progenitors. TMEM219 signaling negatively regulates beta cells at early stages and induces Caspase 8-mediated cell death. Pharmacological blockade of TMEM219 further rescued beta cell precursor and proliferation markers, and decreased cell death, both in islets and in in vitro -derived endocrine progenitors, allowing for beta cell preservation. While addressing the upstream controlling TMEM219 expression, we determined the TMEM219 miRNet; indeed, one of those miRNAs, miR-129-2, is highly expressed in human islets, particularly in patients at risk or with established type 1 diabetes. miR-129-2 mimic downregulated TMEM219 expression in islets, in in vitro embryonic-derived endocrine progenitors and in highly proliferating insulinoma-derived cells. Moreover, miR-129-2 inhibitor induced a TMEM219 overexpression in insulinoma-derived cells, which restored cell proliferation and functional markers, thus acting as endogenous regulator of TMEM219 expression. The TMEM219 upstream regulator miR129-2 controls the fate of beta cell precursors and may unleash their regenerative potentials to replenish beta cells in type 1 diabetes., Competing Interests: PF and FD’A hold a patent on IGFBP3/TMEM219 axis. PF and FD’A hold equity in Enthera S.r.l. MN is an employee of Enthera. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 D’Addio, Assi, Maestroni, Rossi, Usuelli, Petrazzuolo, Nardini, Loretelli, Ben Nasr and Fiorina.)
- Published
- 2024
- Full Text
- View/download PDF
141. Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide.
- Author
-
Lunati ME, Cimino V, Bernasconi D, Gandolfi A, Morpurgo PS, Tinari C, Lazzaroni E, Baruffaldi L, Muratori M, Montefusco L, Pastore I, Rossi A, Franzetti IG, Muratori F, Manfrini R, Disoteo OE, Terranova R, Desenzani P, Girelli A, Ghelardi R, D'Addio F, Ben Nasr M, Berra C, Folli F, Bucciarelli L, and Fiorina P
- Subjects
- Humans, Benzhydryl Compounds therapeutic use, Blood Glucose, Body Weight, Creatinine, Glucose, Glycated Hemoglobin, Hypoglycemic Agents therapeutic use, Treatment Outcome, Diabetes Mellitus, Type 2 drug therapy, Glucagon-Like Peptides, Glucosides, Sodium-Glucose Transporter 2 Inhibitors therapeutic use
- Abstract
Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor and semaglutide, a glucagon-like peptide 1 receptor agonist, have both demonstrated efficacy in glycemic control, reducing blood pressure, body weight, risk of renal and heart failure in type 2 diabetes mellitus. In this observational, real-world, study we aimed to investigate the efficacy of the combination therapy with those two agents over glycemic control. We thus obtained the data of 1335 patients with type 2 diabetes followed by 11 Diabetes centers in Lombardia, Italy. A group of 443 patients was treated with dapagliflozin alone, the other group of 892 patients was treated with the combination therapy of dapagliflozin plus oral semaglutide. We analyzed changes in glycated hemoglobin from baseline to 6 months of follow-up, as well as changes in fasting glycemia, body weight, body mass index, systolic and diastolic pressure, heart rate, creatinine, estimated glomerular filtration rate and albuminuria. Both groups of patients showed an improvement of glycometabolic control after 6 months of treatment; indeed, the treatment with dapagliflozin plus oral semaglutide showed a reduction of glycated hemoglobin of 1.2% as compared to the 0.5% reduction observed in the dapagliflozin alone group. Significant changes were observed in body mass index, fasting plasmatic glucose, blood pressure, total cholesterol, LDL and albumin to creatinine ratio, with a high rate (55%) of near-normalization of glycated hemoglobin. Our real world data confirmed the potential of the oral combination therapy dapagliflozin with semaglutide in inducing pharmacological remission of type 2 diabetes mellitus., Competing Interests: Declaration of Competing Interest None., (Copyright © 2023. Published by Elsevier Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
142. Prevalence and significance of mesentery thickening and lymph nodes enlargement in Crohn's disease.
- Author
-
Sampietro GM, Maconi G, Colombo F, Dilillo D, Fiorina P, D'Addio F, Loretelli C, Mantegazza C, Nebuloni M, Corsi F, Zuccotti G, Ardizzone S, Corona A, and Foschi D
- Subjects
- Humans, Lymph Nodes pathology, Mesentery pathology, Mesentery surgery, Prevalence, Recurrence, Retrospective Studies, Crohn Disease complications, Crohn Disease epidemiology, Crohn Disease surgery
- Abstract
Background: Mesentery thickening and enlarged lymphnodes are typical findings of Crohn's disease (CD), but their role is unknown. Aim of the present study was to evaluate their prevalence and significance on postoperative complications and long-term surgical recurrence after CD surgery., Methods: 1272 consecutive, unselected patients were retrospectively reviewed, divided into 4 groups based on the presence or absence of a thickened mesentery and enlarged lymphnodes, and stratified for primary or recurrent surgical procedure. In all patients but those treated with strictureplasty the mesentery and lymphnodes were removed. Patients' characteristics, peri-operative findings, and long-term recurrence were compared by univariate and multivariate analysis., Results: Thickened mesentery and enlarged lymphnodes were not present in all cases, were typical of ileal location and penetrating behaviour, had a constant decrease over recurrences, were independent of either pre-operative medical therapy or surgical approach, did not increase the duration of surgery and complications, presented similar 20-years recurrence rate to normal mesentery and lymphnodes. Lymphopathy was associated to a worst nutritional status during disease recurrences. At multivariate analysis, age, location, and behaviour, but not mesenteric characteristics, were related to an increased risk of surgical recurrence., Conclusions: This study provides new information on mesentery and lymphnodes in CD patients. Further studies are needed to clarify the appropriate surgical approach., Competing Interests: Declaration of Competing Interest None, (Copyright © 2021. Published by Elsevier Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
143. Novel Soluble Mediators of Innate Immune System Activation in Solid Allograft Rejection.
- Author
-
Usuelli V, Loretelli C, Seelam AJ, Pastore I, D'Addio F, Ben Nasr M, and Fiorina P
- Subjects
- Allografts, Immune System, Immunity, Innate, Transplantation, Homologous, Graft Rejection prevention & control, Organ Transplantation adverse effects
- Abstract
During the past years, solid allograft rejection has been considered the consequence of either cellular- or antibody-mediated reaction both being part of the adaptive immune response, whereas the role of innate immunity has been mostly considered less relevant. Recently, a large body of evidence suggested that the innate immune response and its soluble mediators may play a more important role during solid allograft rejection than originally thought. This review will highlight the role of novel soluble mediators that are involved in the activation of innate immunity during alloimmune response and solid allograft rejection. We will also discuss emerging strategies to alleviate the aforementioned events. Hence, novel, feasible, and safe clinical therapies are needed to prevent allograft loss in solid organ transplantation. Fully understanding the role of soluble mediators of innate immune system activation may help to mitigate solid allograft rejection and improve transplanted recipients' outcomes., Competing Interests: The authors declare no conflicts of interest., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
144. miR-21 antagonism reprograms macrophage metabolism and abrogates chronic allograft vasculopathy.
- Author
-
Usuelli V, Ben Nasr M, D'Addio F, Liu K, Vergani A, El Essawy B, Yang J, Assi E, Uehara M, Rossi C, Solini A, Capobianco A, Rigamonti E, Potena L, Venturini M, Sabatino M, Bottarelli L, Ammirati E, Frigerio M, Castillo-Leon E, Maestroni A, Azzoni C, Loretelli C, Joe Seelam A, Tai AK, Pastore I, Becchi G, Corradi D, Visner GA, Zuccotti GV, Chau NB, Abdi R, Pezzolesi MG, and Fiorina P
- Subjects
- Allografts, Animals, Graft Rejection genetics, Graft Rejection prevention & control, Humans, Macrophages, Mice, Heart Transplantation adverse effects, MicroRNAs genetics
- Abstract
Despite much progress in improving graft outcome during cardiac transplantation, chronic allograft vasculopathy (CAV) remains an impediment to long-term graft survival. MicroRNAs (miRNAs) emerged as regulators of the immune response. Here, we aimed to examine the miRNA network involved in CAV. miRNA profiling of heart samples obtained from a murine model of CAV and from cardiac-transplanted patients with CAV demonstrated that miR-21 was most significantly expressed and was primarily localized to macrophages. Interestingly, macrophage depletion with clodronate did not significantly prolong allograft survival in mice, while conditional deletion of miR-21 in macrophages or the use of a specific miR-21 antagomir resulted in indefinite cardiac allograft survival and abrogated CAV. The immunophenotype, secretome, ability to phagocytose, migration, and antigen presentation of macrophages were unaffected by miR-21 targeting, while macrophage metabolism was reprogrammed, with a shift toward oxidative phosphorylation in naïve macrophages and with an inhibition of glycolysis in pro-inflammatory macrophages. The aforementioned effects resulted in an increase in M2-like macrophages, which could be reverted by the addition of L-arginine. RNA-seq analysis confirmed alterations in arginase-associated pathways associated with miR-21 antagonism. In conclusion, miR-21 is overexpressed in murine and human CAV, and its targeting delays CAV onset by reprogramming macrophages metabolism., (© 2021 The Authors. American Journal of Transplantation published by Wiley Periodicals LLC on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2021
- Full Text
- View/download PDF
145. Strictureplasties performed by laparoscopic approach for complicated Crohn's disease. A prospective, observational, cohort study.
- Author
-
Sampietro GM, Colombo F, Frontali A, Baldi C, Conti L, Dilillo D, Penagini F, Nebuloni M, D'Addio F, Fiorina P, Maconi G, Corsi F, Zuccotti G, Ardizzone S, and Foschi D
- Subjects
- Adolescent, Adult, Case-Control Studies, Crohn Disease complications, Crohn Disease epidemiology, Digestive System Surgical Procedures standards, Feasibility Studies, Female, Humans, Laparoscopy statistics & numerical data, Male, Middle Aged, Postoperative Complications epidemiology, Prospective Studies, Young Adult, Crohn Disease surgery, Digestive System Surgical Procedures methods, Laparoscopy methods
- Abstract
Background: Laparoscopy is considered the best surgical approach for Crohn's Disease (CD), and strictureplasty a reliable alternative to intestinal resection. Nevertheless, their association has never been evaluated., Aim: To investigate feasibility and safety of conventional (SP) and non-conventional (NCSP) strictureplasties, using laparoscopy, for complicated CD., Methods: Starting January 2008, a prospective cohort study was performed, in consecutive, unselected patients, undergoing primary surgery for CD (Group-A). The residential database (CD-CARD) was used for the retrospective extraction of control patients (Group-B). Univariate and multi-variate analysis of pre-operative characteristics, intra-operative findings, morbidity, and intra-abdominal septic complications (IASCs) was performed., Results: Between January 2008 and December 2019, 331 patients received 162 SPs, 138 NCSPs, and 373 resections (Group-A). From the CD-CARD, 227 control patients received 159 SPs, 117 NCSPs, and 271 resections (Group-B) (ns). Preoperatively, Group-A presented batter nutritional status and received more biological therapies, Group-B more steroids. Group-A presented less abdominal abscesses, planned ostomies, minor complications, shorter operating time and hospitalization than Group-B, but similar major complications, IASCs and anastomotic leaks. IASCs were related to older age, elevated inflammatory indices, and preoperative treatment with high-risk drugs., Conclusions: SP and NCSP are feasible by laparoscopy, with low morbidity rate, confirming the advantages of both minimally invasive and conservative surgery., (Copyright © 2021 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
146. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection.
- Author
-
Montefusco L, Ben Nasr M, D'Addio F, Loretelli C, Rossi A, Pastore I, Daniele G, Abdelsalam A, Maestroni A, Dell'Acqua M, Ippolito E, Assi E, Usuelli V, Seelam AJ, Fiorina RM, Chebat E, Morpurgo P, Lunati ME, Bolla AM, Finzi G, Abdi R, Bonventre JV, Rusconi S, Riva A, Corradi D, Santus P, Nebuloni M, Folli F, Zuccotti GV, Galli M, and Fiorina P
- Subjects
- COVID-19 complications, COVID-19 virology, Cohort Studies, Humans, Hyperglycemia complications, Insulin Resistance, Insulin-Secreting Cells pathology, SARS-CoV-2 isolation & purification, Blood Glucose metabolism, COVID-19 blood, Hyperglycemia metabolism
- Abstract
Patients with coronavirus disease 2019 (COVID-19) are reported to have a greater prevalence of hyperglycaemia. Cytokine release as a consequence of severe acute respiratory syndrome coronavirus 2 infection may precipitate the onset of metabolic alterations by affecting glucose homeostasis. Here we describe abnormalities in glycometabolic control, insulin resistance and beta cell function in patients with COVID-19 without any pre-existing history or diagnosis of diabetes, and document glycaemic abnormalities in recovered patients 2 months after onset of disease. In a cohort of 551 patients hospitalized for COVID-19 in Italy, we found that 46% of patients were hyperglycaemic, whereas 27% were normoglycaemic. Using clinical assays and continuous glucose monitoring in a subset of patients, we detected altered glycometabolic control, with insulin resistance and an abnormal cytokine profile, even in normoglycaemic patients. Glycaemic abnormalities can be detected for at least 2 months in patients who recovered from COVID-19. Our data demonstrate that COVID-19 is associated with aberrant glycometabolic control, which can persist even after recovery, suggesting that further investigation of metabolic abnormalities in the context of long COVID is warranted.
- Published
- 2021
- Full Text
- View/download PDF
147. Islet-Derived eATP Fuels Autoreactive CD8 + T Cells and Facilitates the Onset of Type 1 Diabetes.
- Author
-
Tezza S, Ben Nasr M, D'Addio F, Vergani A, Usuelli V, Falzoni S, Bassi R, Dellepiane S, Fotino C, Rossi C, Maestroni A, Solini A, Corradi D, Giani E, Mameli C, Bertuzzi F, Pezzolesi MG, Wasserfall CH, Atkinson MA, Füchtbauer EM, Ricordi C, Folli F, Di Virgilio F, Pileggi A, Dhe-Paganon S, Zuccotti GV, and Fiorina P
- Subjects
- Adenosine Triphosphate analogs & derivatives, Adenosine Triphosphate pharmacology, Animals, Autoimmunity genetics, Autoimmunity physiology, Diabetes Mellitus, Type 1 genetics, Female, Flow Cytometry, Humans, Lymphocyte Activation drug effects, Mice, Mice, Inbred BALB C, Mice, Inbred NOD, Mutation genetics, Receptors, Purinergic P2X7 genetics, Adenosine Triphosphate metabolism, CD8-Positive T-Lymphocytes metabolism, Diabetes Mellitus, Type 1 metabolism, Receptors, Purinergic P2X7 metabolism
- Abstract
Extracellular ATP (eATP) activates T cells by engaging the P2X7R receptor. We identified two loss-of-function P2X7R mutations that are protective against type 1 diabetes (T1D) and thus hypothesized that eATP/P2X7R signaling may represent an early step in T1D onset. Specifically, we observed that in patients with newly diagnosed T1D, P2X7R is upregulated on CD8
+ effector T cells in comparison with healthy control subjects. eATP is released at high levels by human/murine islets in vitro in high-glucose/inflammatory conditions, thus upregulating P2X7R on CD8+ T cells in vitro. P2X7R blockade with oxidized ATP reduces the CD8+ T cell-mediated autoimmune response in vitro and delays diabetes onset in NOD mice. Autoreactive CD8+ T-cell activation is highly dependent upon eATP/P2X7R-mediated priming, while a novel sP2X7R recombinant protein abrogates changes in metabolism and the autoimmune response associated with CD8+ T cells. eATP/P2X7R signaling facilitates the onset of autoimmune T1D by fueling autoreactive CD8+ cells and therefore represents a novel targeted therapeutic for the disorder., (© 2018 by the American Diabetes Association.)- Published
- 2018
- Full Text
- View/download PDF
148. Type 1 Diabetes and Dysfunctional Intestinal Homeostasis.
- Author
-
D'Addio F and Fiorina P
- Subjects
- Animals, Humans, Intestines cytology, Stem Cells metabolism, Diabetes Mellitus, Type 1 complications, Diabetes Mellitus, Type 1 metabolism, Gastrointestinal Diseases etiology, Gastrointestinal Diseases metabolism
- Abstract
Despite the relatively high frequency of gastrointestinal (GI) disorders in individuals with type 1 diabetes (T1D), termed diabetic enteropathy (DE), the pathogenic mechanisms of these disorders remain to be elucidated. While previous studies have assumed that DE is a manifestation of diabetic autonomic neuropathy, other contributing factors such as enteric hormones, inflammation, and microbiota were later recognized. More recently, the emerging role of intestinal stem cells (ISCs) in several GI diseases has led to a new understanding of DE. Given the absence of diagnostic methods and the lack of broadly efficacious therapeutic remedies in DE, targeting factors and pathways that control ISC homeostasis and are dysfunctional in DE may represent a new path for the detection and cure of DE., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
149. Circulating IGF-I and IGFBP3 Levels Control Human Colonic Stem Cell Function and Are Disrupted in Diabetic Enteropathy.
- Author
-
D'Addio F, La Rosa S, Maestroni A, Jung P, Orsenigo E, Ben Nasr M, Tezza S, Bassi R, Finzi G, Marando A, Vergani A, Frego R, Albarello L, Andolfo A, Manuguerra R, Viale E, Staudacher C, Corradi D, Batlle E, Breault D, Secchi A, Folli F, and Fiorina P
- Subjects
- Animals, Colon physiology, Diabetes Complications metabolism, Diabetes Mellitus, Experimental metabolism, Humans, Intestinal Mucosa metabolism, Intestinal Mucosa pathology, Membrane Proteins metabolism, Mice, Proteomics, Colon cytology, Diabetes Complications pathology, Diabetes Mellitus, Experimental pathology, Insulin-Like Growth Factor Binding Protein 3 blood, Insulin-Like Growth Factor I metabolism, Stem Cells physiology
- Abstract
The role of circulating factors in regulating colonic stem cells (CoSCs) and colonic epithelial homeostasis is unclear. Individuals with long-standing type 1 diabetes (T1D) frequently have intestinal symptoms, termed diabetic enteropathy (DE), though its etiology is unknown. Here, we report that T1D patients with DE exhibit abnormalities in their intestinal mucosa and CoSCs, which fail to generate in vitro mini-guts. Proteomic profiling of T1D+DE patient serum revealed altered levels of insulin-like growth factor 1 (IGF-I) and its binding protein 3 (IGFBP3). IGFBP3 prevented in vitro growth of patient-derived organoids via binding its receptor TMEM219, in an IGF-I-independent manner, and disrupted in vivo CoSC function in a preclinical DE model. Restoration of normoglycemia in patients with long-standing T1D via kidney-pancreas transplantation or in diabetic mice by treatment with an ecto-TMEM219 recombinant protein normalized circulating IGF-I/IGFBP3 levels and reestablished CoSC homeostasis. These findings demonstrate that peripheral IGF-I/IGFBP3 controls CoSCs and their dysfunction in DE., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
150. CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival.
- Author
-
D'Addio F, Ueno T, Clarkson M, Zhu B, Vergani A, Freeman GJ, Sayegh MH, Ansari MJ, Fiorina P, and Habicht A
- Subjects
- Animals, Antigen-Presenting Cells immunology, Antigen-Presenting Cells metabolism, Antigens, CD genetics, CD28 Antigens deficiency, CD28 Antigens immunology, CD4 Antigens genetics, CD4 Antigens immunology, Cytokines biosynthesis, Cytotoxicity, Immunologic genetics, Cytotoxicity, Immunologic immunology, GPI-Linked Proteins genetics, GPI-Linked Proteins immunology, Gene Expression, Graft Survival genetics, Heart Transplantation immunology, Heart Transplantation mortality, Histocompatibility Antigens Class I genetics, Histocompatibility Antigens Class I immunology, Immunoglobulin G genetics, Immunologic Memory genetics, Immunologic Memory immunology, Interferon-gamma biosynthesis, Killer Cells, Natural immunology, Killer Cells, Natural metabolism, Lymphocyte Activation immunology, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Knockout, Receptors, Immunologic genetics, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins immunology, Skin Transplantation immunology, Skin Transplantation mortality, T-Lymphocyte Subsets immunology, T-Lymphocyte Subsets metabolism, Transplantation, Homologous, Antigens, CD immunology, Graft Survival drug effects, Graft Survival immunology, Immunoglobulin G immunology, Receptors, Immunologic immunology, Recombinant Fusion Proteins pharmacology, Signal Transduction drug effects
- Abstract
CD160 is a cell surface molecule expressed by most NK cells and approximately 50% of CD8(+) cytotoxic T lymphocytes. Engagement of CD160 by MHC class-I directly triggers a costimulatory signal to TCR-induced proliferation, cytokine production and cytotoxic effector functions. The role of CD160 in alloimmunity is unknown. Using a newly generated CD160 fusion protein (CD160Ig) we examined the role of the novel costimulatory molecule CD160 in mediating CD4(+) or CD8(+) T cell driven allograft rejection. CD160Ig inhibits alloreactive CD8(+) T cell proliferation and IFN-γ production in vitro, in particular in the absence of CD28 costimulation. Consequently CD160Ig prolongs fully mismatched cardiac allograft survival in CD4(-/-), CD28(-/-) knockout and CTLA4Ig treated WT recipients, but not in WT or CD8(-/-) knockout recipients. The prolonged cardiac allograft survival is associated with reduced alloreactive CD8(+) T cell proliferation, effector/memory responses and alloreactive IFN-γ production. Thus, CD160 signaling is particularly important in CD28-independent effector/memory CD8(+) alloreactive T cell activation in vivo and therefore may serve as a novel target for prevention of allograft rejection.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.